Abstract | OBJECTIVES: Fat lesions (FLs) on MRI T1 sequences are considered to be early indicators of structural spinal progression in axial spondyloarthritis ( axSpA) patients. In this post-hoc analysis from RAPID- axSpA, we assess whether tumour necrosis factor inhibitor (TNFi) treatment over 4 years impacts FLs in spinal vertebral edges (VEs) of patients with axSpA. METHODS: In RAPID- axSpA (NCT01087762), a 4-year, phase 3 randomized trial, participants were randomized to certolizumab pegol (CZP; 400 mg loading dose at Weeks 0/2/4 then 200/400 mg every 2/4 weeks) or placebo (PBO) at baseline; PBO-randomized participants switched to CZP at Week 16/24 (denoted PBO-randomized/CZP). Spinal MRI scans were taken at Weeks 0, 12, 48, 96 and 204. Changes in proportions of VEs with FLs are reported as odds ratios ( ORs) between time points. RESULTS: Overall, 136 participants (CZP: 89, PBO-randomized/CZP: 47) had a baseline and ≥1 post-baseline MRI. The OR (95% confidence interval) vs baseline of FLs was higher in PBO-randomized/CZP vs CZP-randomized participants at Weeks 48 [3.35 (2.16-5.19) vs 1.45 (1.07-1.97)], 96 [2.62 (1.77-3.88) vs 1.84 (1.36-2.48)] and 204 [2.55 (1.59-4.06) vs 1.71 (1.23-2.37)]. Across 204 weeks, FLs increased more in VEs with baseline inflammation [Week 204 OR: 4.84 (2.56-9.18)] than those without [OR: 1.15 (0.78-1.71)]. VEs in which inflammation was resolved by Week 12 had lower FL prevalence at Weeks 48, 96 and 204 compared with VEs with unresolved inflammation. CONCLUSIONS: Early and sustained suppression of inflammation mitigates the risk of long-term FL development in the spine in study participants with axSpA evaluated over 4 years. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT01087762.
|
Authors | Xenofon Baraliakos, Sebastian Kruse, Simone E Auteri, Natasha de Peyrecave, Tommi Nurminen, Thomas Kumke, Bengt Hoepken, Jürgen Braun |
Journal | Rheumatology (Oxford, England)
(Rheumatology (Oxford))
Vol. 61
Issue 7
Pg. 2875-2885
(07 06 2022)
ISSN: 1462-0332 [Electronic] England |
PMID | 34791107
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. |
Chemical References |
- Antirheumatic Agents
- Certolizumab Pegol
|
Topics |
- Antirheumatic Agents
(therapeutic use)
- Axial Spondyloarthritis
- Certolizumab Pegol
(therapeutic use)
- Double-Blind Method
- Humans
- Inflammation
(drug therapy)
- Magnetic Resonance Imaging
- Spondylarthritis
(diagnostic imaging, drug therapy)
- Treatment Outcome
|